Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases
Fluticasone propionate – the first carbothioate corticosteroid – has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of patients with dermatological disorders such as at...
Gespeichert in:
| Veröffentlicht in: | Skin pharmacology and physiology 2005-01, Vol.18 (1), p.3-11 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11 |
|---|---|
| container_issue | 1 |
| container_start_page | 3 |
| container_title | Skin pharmacology and physiology |
| container_volume | 18 |
| creator | Roeder, A. Schaller, M. Schäfer-Korting, M. Korting, H.C. |
| description | Fluticasone propionate – the first carbothioate corticosteroid – has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of patients with dermatological disorders such as atopic dermatitis, psoriasis and vitiligo. This glucocorticoid is characterized by high lipophilicity, high glucocorticoid receptor binding and activation, and a rapid metabolic turnover in skin. Although skin blanching following fluticasone propionate exceeds that of corticosteroids of medium strength, several clinical trials demonstrate a low potential for cutaneous and systemic side-effects, even in difficult-to-treat areas like the face, the eyelids and intertriginous areas. Even among paediatric patients with atopic dermatitis, fluticasone propionate proved to be safe and effective. These pharmacological and clinical properties are reflected by the high therapeutic index of this glucocorticoid. |
| doi_str_mv | 10.1159/000081680 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_karger_primary_81680</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>768940441</sourcerecordid><originalsourceid>FETCH-LOGICAL-c392t-904dbdcd17f9424f7e7125d125c528b207ec9562071b23feee06cea6d53e9b6a3</originalsourceid><addsrcrecordid>eNptkM9LwzAUx4MoTqcHz4KE3TxUk7RJ2qPMTYWBg008ljR90e5HW5P0sP_ezM158cHj_fq89-CL0BUld5Ty7J4ES6lIyRE6o0KQiPOYHx9yJnvo3LkFIUxIKk5Rj3JB0iSTZ-h9pgz4DVZ1iUfGVFrpDW4MHq86HwrX1ICntmmrplYecFVj_wl4HhparfDcgvJrqP12ZbYM08fKgXLgLtCJUSsHl_vYR2_j0Xz4HE1en16GD5NIxxnzUUaSsih1SaXJEpYYCZIyXgbXnKUFIxJ0xkWItGCxAQAiNChR8hiyQqi4jwa7u61tvjpwPl80na3Dy5wxzkQqpQjQ7Q7StnHOgslbW62V3eSU5FsF84OCgb3ZH-yKNZR_5F6yAFzvgKWyH2APwO_64N_pbDr9AfK2NPE3r1B-7Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>225268776</pqid></control><display><type>article</type><title>Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases</title><source>Karger e-journals Complete Collection</source><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Roeder, A. ; Schaller, M. ; Schäfer-Korting, M. ; Korting, H.C.</creator><creatorcontrib>Roeder, A. ; Schaller, M. ; Schäfer-Korting, M. ; Korting, H.C.</creatorcontrib><description>Fluticasone propionate – the first carbothioate corticosteroid – has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of patients with dermatological disorders such as atopic dermatitis, psoriasis and vitiligo. This glucocorticoid is characterized by high lipophilicity, high glucocorticoid receptor binding and activation, and a rapid metabolic turnover in skin. Although skin blanching following fluticasone propionate exceeds that of corticosteroids of medium strength, several clinical trials demonstrate a low potential for cutaneous and systemic side-effects, even in difficult-to-treat areas like the face, the eyelids and intertriginous areas. Even among paediatric patients with atopic dermatitis, fluticasone propionate proved to be safe and effective. These pharmacological and clinical properties are reflected by the high therapeutic index of this glucocorticoid.</description><identifier>ISSN: 1660-5527</identifier><identifier>EISSN: 1660-5535</identifier><identifier>DOI: 10.1159/000081680</identifier><identifier>PMID: 15608497</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Administration, Cutaneous ; Androstadienes - adverse effects ; Androstadienes - pharmacokinetics ; Androstadienes - therapeutic use ; Dermatitis, Atopic - drug therapy ; Dermatologic Agents - adverse effects ; Dermatologic Agents - pharmacokinetics ; Dermatologic Agents - therapeutic use ; Fluticasone ; Humans ; Psoriasis - drug therapy ; Review ; Skin Diseases - drug therapy ; Vitiligo - drug therapy</subject><ispartof>Skin pharmacology and physiology, 2005-01, Vol.18 (1), p.3-11</ispartof><rights>2005 S. Karger AG, Basel</rights><rights>Copyright 2005 S. Karger AG, Basel.</rights><rights>Copyright (c) 2005 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c392t-904dbdcd17f9424f7e7125d125c528b207ec9562071b23feee06cea6d53e9b6a3</citedby><cites>FETCH-LOGICAL-c392t-904dbdcd17f9424f7e7125d125c528b207ec9562071b23feee06cea6d53e9b6a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15608497$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Roeder, A.</creatorcontrib><creatorcontrib>Schaller, M.</creatorcontrib><creatorcontrib>Schäfer-Korting, M.</creatorcontrib><creatorcontrib>Korting, H.C.</creatorcontrib><title>Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases</title><title>Skin pharmacology and physiology</title><addtitle>Skin Pharmacol Physiol</addtitle><description>Fluticasone propionate – the first carbothioate corticosteroid – has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of patients with dermatological disorders such as atopic dermatitis, psoriasis and vitiligo. This glucocorticoid is characterized by high lipophilicity, high glucocorticoid receptor binding and activation, and a rapid metabolic turnover in skin. Although skin blanching following fluticasone propionate exceeds that of corticosteroids of medium strength, several clinical trials demonstrate a low potential for cutaneous and systemic side-effects, even in difficult-to-treat areas like the face, the eyelids and intertriginous areas. Even among paediatric patients with atopic dermatitis, fluticasone propionate proved to be safe and effective. These pharmacological and clinical properties are reflected by the high therapeutic index of this glucocorticoid.</description><subject>Administration, Cutaneous</subject><subject>Androstadienes - adverse effects</subject><subject>Androstadienes - pharmacokinetics</subject><subject>Androstadienes - therapeutic use</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Dermatologic Agents - adverse effects</subject><subject>Dermatologic Agents - pharmacokinetics</subject><subject>Dermatologic Agents - therapeutic use</subject><subject>Fluticasone</subject><subject>Humans</subject><subject>Psoriasis - drug therapy</subject><subject>Review</subject><subject>Skin Diseases - drug therapy</subject><subject>Vitiligo - drug therapy</subject><issn>1660-5527</issn><issn>1660-5535</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNptkM9LwzAUx4MoTqcHz4KE3TxUk7RJ2qPMTYWBg008ljR90e5HW5P0sP_ezM158cHj_fq89-CL0BUld5Ty7J4ES6lIyRE6o0KQiPOYHx9yJnvo3LkFIUxIKk5Rj3JB0iSTZ-h9pgz4DVZ1iUfGVFrpDW4MHq86HwrX1ICntmmrplYecFVj_wl4HhparfDcgvJrqP12ZbYM08fKgXLgLtCJUSsHl_vYR2_j0Xz4HE1en16GD5NIxxnzUUaSsih1SaXJEpYYCZIyXgbXnKUFIxJ0xkWItGCxAQAiNChR8hiyQqi4jwa7u61tvjpwPl80na3Dy5wxzkQqpQjQ7Q7StnHOgslbW62V3eSU5FsF84OCgb3ZH-yKNZR_5F6yAFzvgKWyH2APwO_64N_pbDr9AfK2NPE3r1B-7Q</recordid><startdate>200501</startdate><enddate>200501</enddate><creator>Roeder, A.</creator><creator>Schaller, M.</creator><creator>Schäfer-Korting, M.</creator><creator>Korting, H.C.</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>200501</creationdate><title>Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases</title><author>Roeder, A. ; Schaller, M. ; Schäfer-Korting, M. ; Korting, H.C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c392t-904dbdcd17f9424f7e7125d125c528b207ec9562071b23feee06cea6d53e9b6a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Administration, Cutaneous</topic><topic>Androstadienes - adverse effects</topic><topic>Androstadienes - pharmacokinetics</topic><topic>Androstadienes - therapeutic use</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Dermatologic Agents - adverse effects</topic><topic>Dermatologic Agents - pharmacokinetics</topic><topic>Dermatologic Agents - therapeutic use</topic><topic>Fluticasone</topic><topic>Humans</topic><topic>Psoriasis - drug therapy</topic><topic>Review</topic><topic>Skin Diseases - drug therapy</topic><topic>Vitiligo - drug therapy</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Roeder, A.</creatorcontrib><creatorcontrib>Schaller, M.</creatorcontrib><creatorcontrib>Schäfer-Korting, M.</creatorcontrib><creatorcontrib>Korting, H.C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Skin pharmacology and physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Roeder, A.</au><au>Schaller, M.</au><au>Schäfer-Korting, M.</au><au>Korting, H.C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases</atitle><jtitle>Skin pharmacology and physiology</jtitle><addtitle>Skin Pharmacol Physiol</addtitle><date>2005-01</date><risdate>2005</risdate><volume>18</volume><issue>1</issue><spage>3</spage><epage>11</epage><pages>3-11</pages><issn>1660-5527</issn><eissn>1660-5535</eissn><abstract>Fluticasone propionate – the first carbothioate corticosteroid – has been classified as a potent anti-inflammatory drug for dermatological use. It is available as 0.05% cream and 0.005% ointment formulations for the acute and maintenance treatment of patients with dermatological disorders such as atopic dermatitis, psoriasis and vitiligo. This glucocorticoid is characterized by high lipophilicity, high glucocorticoid receptor binding and activation, and a rapid metabolic turnover in skin. Although skin blanching following fluticasone propionate exceeds that of corticosteroids of medium strength, several clinical trials demonstrate a low potential for cutaneous and systemic side-effects, even in difficult-to-treat areas like the face, the eyelids and intertriginous areas. Even among paediatric patients with atopic dermatitis, fluticasone propionate proved to be safe and effective. These pharmacological and clinical properties are reflected by the high therapeutic index of this glucocorticoid.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>15608497</pmid><doi>10.1159/000081680</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1660-5527 |
| ispartof | Skin pharmacology and physiology, 2005-01, Vol.18 (1), p.3-11 |
| issn | 1660-5527 1660-5535 |
| language | eng |
| recordid | cdi_karger_primary_81680 |
| source | Karger e-journals Complete Collection; MEDLINE; Alma/SFX Local Collection |
| subjects | Administration, Cutaneous Androstadienes - adverse effects Androstadienes - pharmacokinetics Androstadienes - therapeutic use Dermatitis, Atopic - drug therapy Dermatologic Agents - adverse effects Dermatologic Agents - pharmacokinetics Dermatologic Agents - therapeutic use Fluticasone Humans Psoriasis - drug therapy Review Skin Diseases - drug therapy Vitiligo - drug therapy |
| title | Safety and Efficacy of Fluticasone Propionate in the Topical Treatment of Skin Diseases |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T14%3A37%3A37IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Safety%20and%20Efficacy%20of%20Fluticasone%20Propionate%20in%20the%20Topical%20Treatment%20of%20Skin%20Diseases&rft.jtitle=Skin%20pharmacology%20and%20physiology&rft.au=Roeder,%20A.&rft.date=2005-01&rft.volume=18&rft.issue=1&rft.spage=3&rft.epage=11&rft.pages=3-11&rft.issn=1660-5527&rft.eissn=1660-5535&rft_id=info:doi/10.1159/000081680&rft_dat=%3Cproquest_karge%3E768940441%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=225268776&rft_id=info:pmid/15608497&rfr_iscdi=true |